Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

RGNX vs CRVS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CRVS Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 7–1 Matrix Metrics)

CRVS Overall Winner 6-Pillar Tally: RGNX 3 – 3 CRVS Matrix Metrics: RGNX 1 – 7 CRVS

As of Nov 16, 2026, Corvus Pharmaceuticals, Inc. (CRVS) is the stronger overall head-to-head candidate over REGENXBIO Inc. (RGNX) in the Tradestie Institutional Equity Comparison Engine, winning 7–1 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). RGNX carries a Unified Composite Score of 45.3/100 (HOLD) at $7.47 (N/M Forward P/E, -120.4% operating margin), whereas CRVS carries 34.3/100 (SELL) at $10.55 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While RGNX currently prints a higher short-term Unified Composite Score (45.3/100 HOLD vs. CRVS 34.3/100 SELL), CRVS captures the overall institutional head-to-head verdict (7–1 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -120.4% operating margin) and revenue trajectory (+0.0% vs. -69.2% YoY).
  • Technical & Structure Timing Caution: RGNX is currently in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 48.3); meanwhile CRVS is in a Breakdown options structure phase (RSI 48.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About RGNX vs CRVS
RGNX NASDAQ
REGENXBIO Inc.
Biological Products, (No Disgnostic Substances)
$7.47
-2.23% 1D
Market Cap $500.9M
TTM Revenue $154M
Forward P/E N/M
Beta / 30D Vol 1.81β · 76% Vol
Unified Composite Score
45.3 / 100 HOLD
Tech 36.0 Fund 44.0 Flow 69.0 Mom 50.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -12.2%) with fading momentum, RSI 48
RSI-14: 48.3 · SMA20: $7.42 · SMA50: $7.63
CRVS NASDAQ Head-to-Head Winner
Corvus Pharmaceuticals, Inc.
Pharmaceutical Preparations
$10.55
-0.85% 1D
Market Cap $895.8M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.89β · 71% Vol
Unified Composite Score
34.3 / 100 SELL
Tech 20.0 Fund 46.0 Flow 72.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 48
RSI-14: 48.5 · SMA20: $10.48 · SMA50: $11.10

6-Pillar Scorecard Institutional Category Breakdown (RGNX 3 – 3 CRVS)

Columns: Metric · RGNX · CRVS
1. Valuation Multiples RGNX
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio 0.26x N/M
EV / Revenue 3.1x N/M
2. Growth & Scale CRVS
Revenue Growth (YoY) -69.2% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $154M N/A
Market Cap $500.9M $895.8M
3. Profitability & Quality CRVS
Gross Margin -64.5% N/A
Operating Margin -120.4% 0.0%
Net Profit Margin -113.9% 0.0%
Return on Equity (ROE) -113.2% -45.9%
4. Balance Sheet & Cash Flow RGNX
Cash Generation (TTM) -$155M -$48M
Cash Flow Margin -100.6% N/A
Net Cash / Leverage $29M Net Cash $14M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CRVS
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 349.6% (52nd %ile) 79.7% (8th %ile)
Put/Call OI Skew N/A 0.01x (Call-Skewed)
OBV Trend / Tech Phase ACCUMULATION · Distribution NEUTRAL · Neutral
6. R&D & Supply-Chain Moat RGNX
OpEx & R&D Intensity 55.9% of Rev ($86M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: RGNX (1) vs CRVS (7)
Institutional Metric RGNX CRVS Criterion Row Edge
Market Capitalization
Scale
$500.9M $895.8M Larger Scale CRVS
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-69.2% +0.0% Higher Growth CRVS
Operating Margin (TTM)
Profitability
-120.4% 0.0% Higher Margin CRVS
Net Profit Margin
Profitability
-113.9% 0.0% Higher Margin CRVS
Return on Equity (ROE)
Capital Efficiency
-113.2% -45.9% Higher ROE CRVS
52-Week Range Position
Momentum
19% ($5–$16) 20% ($6–$27) Stronger Trend CRVS
Beta / 30D Volatility
Risk Regime
1.81β · 76% Vol 1.89β · 71% Vol Lower Realized Risk CRVS
Unified Institutional Score
Composite Signal
45.3 / 100 (HOLD) 34.3 / 100 (SELL) Higher Composite RGNX
Trailing 12M Revenue (USD)
Operating Scale
$154M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
-64.5% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.26x PEG · 3.1x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$155M ($29M Net Cash) -$48M ($14M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CRVS +2.95 pp
RGNX: +7.87% · CRVS: +10.82%
3M Horizon CRVS +3.66 pp
RGNX: -32.52% · CRVS: -28.86%
6M Horizon RGNX +45.81 pp
RGNX: +32.21% · CRVS: -13.6%
1Y Horizon CRVS +67.7 pp
RGNX: -35.82% · CRVS: +31.88%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on RGNX vs CRVS. Trailing 12-month operating profitability (RGNX -120.4% vs CRVS 0.0%) and valuation multiples (RGNX N/M vs CRVS N/M Forward P/E) are benchmarked directly in Pillar 4 below.

RGNX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$154M
Gross Margin-64.5%
Op. Margin-120.4%
ROE / Fwd P/E-113.2% · N/M
CRVS ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-45.9% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
RGNX BREAKDOWN
91d in phase · OBV ACCUMULATION
Current IV 349.6%
IV Percentile 52nd %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact RGNX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CRVS BREAKDOWN
91d in phase · OBV NEUTRAL
Current IV 79.7%
IV Percentile 8th %ile
Put/Call OI Skew 0.01x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact CRVS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
RGNX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $500.9M market capitalization and -120.4% operating margin.
OpEx & R&D Reinvestment 55.9% of Rev ($86M)
90D Engineering Disclosures 0 Published
CRVS Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $895.8M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ RGNX vs CRVS Key Questions & Quantitative Answers

As of Nov 16, 2026, Corvus Pharmaceuticals, Inc. (CRVS) is the stronger overall head-to-head candidate over REGENXBIO Inc. (RGNX) in the Tradestie Institutional Equity Comparison Engine, winning 7–1 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). RGNX carries a Unified Composite Score of 45.3/100 (HOLD) at $7.47 (N/M Forward P/E, -120.4% operating margin), whereas CRVS carries 34.3/100 (SELL) at $10.55 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While RGNX currently prints a higher short-term Unified Composite Score (45.3/100 HOLD vs. CRVS 34.3/100 SELL), CRVS captures the overall institutional head-to-head verdict (7–1 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -120.4% operating margin) and revenue trajectory (+0.0% vs. -69.2% YoY). Technical & Structure Timing Caution: RGNX is currently in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 48.3); meanwhile CRVS is in a Breakdown options structure phase (RSI 48.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CRVS leads the Growth & Scale pillar: RGNX posts -69.2% YoY revenue growth and +0.0% YoY earnings growth on $154M TTM revenue (-64.5% gross margin, -120.4% operating margin), compared with CRVS at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, RGNX generates $154M in USD-normalized revenue versus N/A for CRVS. In operating R&D and SG&A reinvestment, RGNX deploys 55.9% of Rev ($86M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CRVS.

RGNX screens cheaper on headline valuation multiples. RGNX trades at N/M Forward P/E, N/M Trailing P/E, 0.26x PEG, and 3.1x EV/Revenue (-100.6% FCF margin), whereas CRVS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against RGNX (-113.2% ROE) versus CRVS (-45.9% ROE) capital efficiency.

In options market volatility and institutional positioning, RGNX carries 349.6% implied volatility (52nd %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.81β · 76% Vol realized risk). By comparison, CRVS carries 79.7% implied volatility (8th %ile, Compressed (<25th %ile)), a 0.01x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.89β · 71% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.